Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Access to Hepatitis C Treatment Through State AIDS Drug Assistance Programs (ADAPs)

May 31, 2007

The Henry J. Kaiser Family Foundation and the National Association of State and Territorial AIDS Directors (NASTAD) released the 2007 National ADAP Monitoring Project Annual Report on April 10th, 2007.

Access to hepatitis C treatment is crucial for HIV/HCV coinfected people. Although hepatitis C can be treated, HCV-associated end-stage liver disease has become a leading cause of death among HIV-positive people in the US.

Although funding shortfalls and increasing need mean that the majority of ADAPs are currently unable to provide pegylated interferon and ribavirin, some are still covering HCV treatment and/or adjunctive therapies used to manage side effects (see table of State ADAP Coverage below). Some State ADAPs offer hepatitis A (HAV) and hepatitis B (HBV) vaccines, which are recommended for people with HIV and hepatitis C who are susceptible to these viruses.

Advertisement
If your State ADAP does not cover hepatitis C treatment, you may be able to obtain it through patient assistance programs sponsored by Roche and Schering.

  • Roche Patient Assistance Foundation: 1-877-75ROCHE (877-757-6243)

  • Schering Commitment to Care (1-800-521-7157)

  • Direct link to Schering's Commitment to Care Application (accessed May 21 2007): www.schering-plough.com/pdf/commitapp.pdf


State ADAP Coverage: Hepatitis A (HAV) & Hepatitis B (HBV) Vaccines, Hepatitis C Treatment, Growth Factors, & Selective Serotonin Reuptake Inhibitors (SSRIs) as of May 2007
StateIFN (PEG, Standard, Consensus)RBVSSRIs/
Other*
Epoetin-
Alfa
FilgrastimHAV & HBV VaccineWaiting List/ Other Cost Containment
ALABAMA


X

Capped enrollment
ALASKA




X
ARIZONAPEG-IFNXXXXX
ARKANSAS






CALIFORNIAStandard IFNXXXXX
COLORADO






CONNECTICUTPEG-IFNXX
XX
DELAWAREPEG-IFNXXXX

DISTRICT OF COLUMBIAStandard IFNXXX


FLORIDA


XXXLowered income eligibility
GEORGIA


X


HAWAII

XXX

IDAHO





Cost containment anticipated before 3/31/08
ILLINOISStandard IFN





INDIANA

X


Capped enrollment
IOWA






KANSAS






KENTUCKY




XCost containment anticipated before 3/31/08
LOUISIANA






MAINE






MARYLANDPEG-IFN, Standard IFN XX
X

MASSACHUSETTSAll FDA-approved drugs are covered**
MICHIGANPEG-IFN, Standard IFNXXXXXFormulary management
MINNESOTA

X



MISSISSIPPIPEG-IFN XX


Lowered medical eligibility
MISSOURI

X

X
MONTANA

XXX
Waiting list
NEBRASKA

XXX

NEVADA

XX


NEW HAMPSHIRE
XXX

Cost containment anticipated before 3/31/08
NEW JERSEYAll FDA-approved drugs are covered**
NEW MEXICO

XX
X
NEW YORKPEG-IFNXXXXX
NORTH CAROLINA

X



NORTH DAKOTA

X

X
OHIO

X
X

OKLAHOMA






OREGON


XX

PENNSYLVANIAPEG-IFNX
XXX
PUERTO RICOPEG-IFN, Standard IFNXXXX
Waiting List
RHODE ISLANDPEG-IFN, Standard IFNXX


Lowered income eligibility; additional cost containment anticipated by 3/31/08
SOUTH CAROLINA

X

XWaiting List; reduced formulary; capped enrollment
SOUTH DAKOTA

X

X
TENNESSEEPEG-IFNXX
X

TEXAS






U.S. VIRGIN ISLANDS





Client cost sharing; additional cost containment anticipated by 3/31/08
UTAH






VERMONT

X
XX
VIRGINIAPEG-IFNX
X
X
WASHINGTONPEG-IFN, Standard IFNXXX
X
WEST VIRGINIA






WISCONSINPEG-IFNXX (Elavil only)

X
WYOMING
X


X


* May include anti-anxiety agents, anti-depressants, anti-psychotics, mood stabilizers, and other psychiatric medications.

** With certain exclusions.

Sources:

  1. Henry J. Kaiser Family Foundation, National Alliance of State and Territorial AIDS Directors (NASTAD). National ADAP Monitoring Project, Annual Report, April 2007. ADAP Formularies. Available on-line at: www.kff.org/hivaids/7619.cfm (accessed on May 9th, 2007).

  2. NASTAD. ADAP Watch. April 2007. Available on-line at: www.nastad.org/Publications/adapwatch.aspx (accessed on May 9th, 2007).

Thanks to Britten Ginsburg, Murray Penner, Beth Crutsinger-Perry and Chris Taylor at NASTAD.

Tracy Swan is TAG's Coinfection Project Director.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Treatment Action Group.
 
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More News on Hepatitis C Treatment

Tools
 

Advertisement